NY-ESO-1 is a Ubiquitous Immunotherapeutic Target Antigen for Patients with Myxoid/ Round Cell Liposarcoma

BACKGROUND: Myxoid/ round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for more than one third of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY-E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pollack, Seth M., Jungbluth, Achim A., Hoch, Benjamin L., Farrar, Erik A., Bleakley, Marie, Schneider, David J., Loggers, Elizabeth T., Rodler, Eve, Eary, Janet F., Conrad, Ernest U., Jones, Robin L., Yee, Cassian
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3361576/
https://ncbi.nlm.nih.gov/pubmed/22359263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.27446
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados